UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 29, 2012
Skystar Bio-Pharmaceutical Company
(Exact name of registrant as specified in
its charter)
______________
| Nevada |
001-34394 |
33-0901534 |
| (State or Other Jurisdiction |
(Commission |
(I.R.S. Employer |
| of Incorporation) |
File Number) |
Identification No.) |
4/F Building B Chuangye Square, No. 48
Keji Road,
Gaoxin District, Xi’an, Shaanxi
Province, P.R. China
(Address of Principal Executive Office)
(Zip Code)
(8629) 8819-3188
(Registrant’s telephone number, including
area code)
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 4.01 Change
in Registrant’s Certifying Accountant
Effective as of June
29, 2012, Crowe Horwath LLP resigned as independent auditors of Skystar Bio-Pharmaceutical Company (the “Company”).
The reports of Crowe
Horwath LLP on the registrant’s financial statements as of December 31, 2011 and 2010 and for the years ended December 31,
2011 and 2010 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty,
audit scope, or accounting principles. In connection with the audits of the registrant’s financial statements for the fiscal
periods ended December 31, 2011 and 2010, and through June 29, 2012, there were: (i) no disagreements between the registrant and
Crowe Horwath LLP on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedure,
which disagreements, if not resolved to the satisfaction of Crowe Horwath LLP, would have caused Crowe Horwath LLP to make reference
to the subject matter of the disagreement in its reports on the registrant’s financial statements for such periods, and (ii)
no reportable events within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.
The registrant provided
Crowe Horwath LLP a copy of the disclosures contained herein and requested that Crowe Horwath LLP furnish it with a letter addressed
to the Securities and Exchange Commission stating whether or not Crowe Horwath LLP agrees with its statements in this Item 4.01.
A copy of the letter dated July 6, 2012, furnished by Crowe Horwath LLP in response to such request, is filed as Exhibit 16 to
this Form 8-K.
On June 29, 2012, the
Audit Committee of the Board of Directors of the Company engaged Crowe Horwath (HK) CPA Limited (“Crowe HK”) as the
Company’s independent registered accounting firm.
During its two most
recent fiscal years ended December 31, 2011 and 2010, and the subsequent interim period through the engagement of Crowe HK on June
29, 2012, the registrant did not consult with Crowe HK on (i) the application of accounting principles to a specified transaction,
either completed or proposed, or the type of audit opinion that might be rendered on the registrant’s financial statements,
and Crowe HK did not provide either a written report or oral advice to the registrant that was an important factor considered by
the registrant in reaching a decision as to any accounting, auditing, or financial reporting issue; or (ii) the subject of any
disagreement, as defined in Item 304 (a)(1)(iv) of Regulation S-K and the related instructions, or a reportable event within the
meaning set forth in Item 304(a)(1)(v) of Regulation S-K.
Item 9.01 Financial
Statement and Exhibits.
Exhibit 16.1 Letter
from Crowe Horwath LLP
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| |
Skystar Bio-Pharmaceutical Company |
| |
|
|
| |
|
|
| |
By: |
/s/ Bing Mei |
| |
|
Chief Financial Officer |
| |
|
Date: July 6, 2012
